Antares Pharma to Host Third Quarter 2012 Earnings Call

  Antares Pharma to Host Third Quarter 2012 Earnings Call

Business Wire

EWING, N.J. -- November 02, 2012

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third
quarter 2012 financial results before the market opens on Wednesday, November
7, 2012, and host a conference call shortly thereafter at 8:30 a.m. ET
(Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and
Chief Executive Officer, and Robert F. Apple, Executive Vice President, Chief
Financial Officer, and President of the Parenteral Products Division, will
host the call.

Interested parties may participate in the conference call by dialing
1-877-941-1465 (US) or 1-480-629-9772 (international), 5-10 minutes prior to
the start of the call. A replay of the conference call will be available
approximately 2 hours after the call’s conclusion through 12:00 p.m. ET
(Eastern Time) on November 21, 2012 by dialing 1-800-406-7325 (US) or
1-303-590-3030 (international), and entering the access code 4572975. An audio
web cast and archive of the conference call will also be available under the
investor relations section of the Antares Web site at www.antarespharma.com.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products
and topical gel-based medicines. The Company's technology platforms include
VIBEX™ disposable Medi-Jet, disposable multi-use pen injectors and Vision™
reusable needle-free injectors marketed as Tjet^® and Zomajet^® by Teva
Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring),
respectively. Antares Pharma has a multi-product deal with Teva that includes
Tev-Tropin^® human growth hormone (hGH), VIBEX epinephrine and several other
products. Antares Pharma’s partnership with Ferring includes Zomacton^® hGH.
In the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment
for overactive bladder that is marketed by Watson Pharmaceuticals, Inc.
Elestrin^® (estradiol gel) is FDA approved for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause, and is
marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the
U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs
the manufacturing and marketing of the Company’s reusable needle-free
injection devices and related disposables, and develops its disposable
pressure-assisted VIBEX Medi-Jet and pen injector systems. The Company’s
corporate head office and Product Development Group are located in Ewing, New
Jersey.

Contact:

Antares Pharma, Inc.
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com